EMBER THERAPEUTICS, INC.

Ajouter à une liste

Instrument Inactif

Autres langues Ember Therapeutics, Inc.

Actions

EMBT

US29082W1099

Autres langues

29/05/22	Alternative Liquidity Index LP Announces an Extension of the Tender Offer for Ember Therapeutics, Inc.
18/11/21	Moore Kuehn Encourages EMBT, VSAT, IHC and CSPR Investors to Contact Law Firm
16/08/19	Viscogliosi Brothers LLC cancelled the acquisition of OP-1 Portfolio Program from Ember Therapeutics, Inc..
16/08/18	Viscogliosi Brothers LLC entered into a letter of intent to acquire OP-1 Portfolio Program from Ember Therapeutics, Inc..
08/09/16	Ember Therapeutics, Inc. acquired the assets of of Dermasilk Brands, Inc. from Midwood Distributors, Inc. for $1.3 million.
06/07/16	Knight Therapeutics Inc. and Ember Therapeutics, Inc. Expand Distribution Partnership
21/03/16	Ember Therapeutics, Inc. entered into a definitive agreement to acquire the assets of Migralex, Inc. for $0.87 million.
16/03/16	Ember Therapeutics, Inc. acquired ICX-RHY/Vavelta from Intercytex Limited for $1.1 million.
24/02/16	American Home Alliance Corp will Change its Ticker to EMBT from AHLL
24/02/16	AMERICAN HOME ALLIANCE CORP will Change its Name to Ember Therapeutics, Inc
03/02/16	Ember Therapeutics, Inc. acquired American Home Alliance Corp. in a reverse merger transaction.
19/10/15	Ember Therapeutics, Inc. Announces Initial Positive Results from a Phase 2 Trial of BMP-7
12/03/15	Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others for $6 million.
31/12/14	Ember Therapeutics, Inc. acquired Worldwide License of BMP-7 and OP-1 Portfolio from Stryker Corporation.
27/09/12	Ember Therapeutics, Inc. Announces Publication of Key Preclinical Data Demonstrating Inhibition of Transient Receptor Potential Vanilloid
30/05/12	Ember Therapeutics, Inc. Announces Management Appointments
31/03/12	Ember Therapeutics, Inc. Closes License Deal with Joslin Diabetes Center

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Espace mes listes

Palmarès

Suite du Palmarès

Palmarès

Suite du Palmarès

Devises / Forex

Matières Premières

Cryptomonnaies

Taux d'Intérêts

DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !

PROFITEZ-EN MAINTENANT